SE0103838D0 - Pharmaceutical formulation & product - Google Patents

Pharmaceutical formulation & product

Info

Publication number
SE0103838D0
SE0103838D0 SE0103838A SE0103838A SE0103838D0 SE 0103838 D0 SE0103838 D0 SE 0103838D0 SE 0103838 A SE0103838 A SE 0103838A SE 0103838 A SE0103838 A SE 0103838A SE 0103838 D0 SE0103838 D0 SE 0103838D0
Authority
SE
Sweden
Prior art keywords
alpha
drug
formulation
methylpropiono
fluorophenylsulphonyl
Prior art date
Application number
SE0103838A
Other languages
English (en)
Inventor
Nicola Bateman
Julie Cahill
Neill Carman
Ian Cockshott
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103838A priority Critical patent/SE0103838D0/sv
Publication of SE0103838D0 publication Critical patent/SE0103838D0/sv
Priority to PCT/GB2002/005158 priority patent/WO2003043630A1/en
Priority to AU2002339169A priority patent/AU2002339169A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE0103838A 2001-11-16 2001-11-16 Pharmaceutical formulation & product SE0103838D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0103838A SE0103838D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product
PCT/GB2002/005158 WO2003043630A1 (en) 2001-11-16 2002-11-14 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor
AU2002339169A AU2002339169A1 (en) 2001-11-16 2002-11-14 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103838A SE0103838D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Publications (1)

Publication Number Publication Date
SE0103838D0 true SE0103838D0 (sv) 2001-11-16

Family

ID=20286022

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103838A SE0103838D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Country Status (3)

Country Link
AU (1) AU2002339169A1 (sv)
SE (1) SE0103838D0 (sv)
WO (1) WO2003043630A1 (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
US10532028B2 (en) * 2005-07-28 2020-01-14 Isp Investments Llc Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
WO2008092057A2 (en) 2007-01-26 2008-07-31 Isp Investments Inc. Formulation process method to produce spray dried products
CN104146974B (zh) * 2014-08-14 2016-09-07 杭州华东医药集团新药研究院有限公司 一种含来曲唑的组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4318371A1 (de) * 1993-05-28 1994-12-01 Schering Ag Mittel, enthaltend eine Verbindung mit antiandrogener sowie eine Verbindung mit kompetitiver, progesteronantagonistischer Wirkung
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
CN1503662A (zh) * 2001-02-27 2004-06-09 药物制剂
MXPA03008999A (es) * 2001-04-02 2004-02-12 Astrazeneca Ab Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp.

Also Published As

Publication number Publication date
WO2003043630A1 (en) 2003-05-30
AU2002339169A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
IS6970A (is) Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
AR032912A1 (es) Formulacion farmaceutica
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
CY1115056T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν φεντανυλη για ενδορινικη χορηγηση
SE0103839D0 (sv) Pharmaceutical formulation & product
EP1423107A4 (en) FATTY ALCOHOL DRUG CONJUGATES
SE0202857D0 (sv) Method and compositions for preventing hormone induced adverse effects
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
HK1068606A1 (en) Novel aminobenzoephenones
PE20040990A1 (es) Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos
SE0103838D0 (sv) Pharmaceutical formulation & product
SE0103424D0 (sv) Pharmaceutical formulation
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
BRPI0407611A (pt) agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo
NO20064753L (no) Kombinasjonsterapi
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
SE0102887D0 (sv) New formulation
NO20026032D0 (no) Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer
JOP20220038A1 (ar) عوامل مضادة للملاريا
EP1374873A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUPPRESSION OF SIDE EFFECTS CAUSED BY RADIATION THERAPY AND CHEMOTHERAPY